Soft -tissue sarcomas arising in the skin of the external ear have a better prognosis than might be expected based on the behavior of other sarcomas. Currently there are a few major case series analyzing soft -tissue sarcomas and the factors related to their prognosis. Th e purpose of this study was to determine the behavior of these tumors and attempt to defi ne factors aff ecting prognosis. We extracted data from the Surveillance Epidemiology and End Result (SEER) 17 Registry and identifi ed a total of 297 patients with sarcoma of the external ear who were included in the registry from 1973from to 2004 patients were diagnosed with malignant fi brous histiocytoma. Dermatofi brosarcoma was the second most prevalent soft -tissue sarcoma (56 patients; 18.9%), followed by leiomyosarcoma (27 patients; 9.1%). Th e overall 5-year survival rate of patients with all histologic types of STS of the external ear was 78.5%.
Introduction
Soft -tissue sarcomas (STSs) are relatively rare malignancies that arise primarily from mesenchymal connectivetissue elements and occur most commonly in the tissues of the upper and lower extremities. Approximately 12% of STS tumors are found in the head and neck region, although only a small proportion of these originate in the external ear. 1 STSs of the external ear aff ect mostly white individuals, with a slight male preponderance. 2 STSs arising in the head and neck region are associated with the highest local recurrence rates and lowest disease-specifi c survival rates of all soft tissue sarcomas. 2, 3 Treatment is surgical resection with wide margins and adjuvant radiation as needed.
Because the head and neck region is a complex area with many vital structures, the clinical behavior of each tumor depends on its site of occurrence within the head and neck. For example, tumors of the external ear can extend medially to the middle ear and temporal bone, leading to hearing loss, facial paralysis, vertigo, and a signifi cant surgical challenge in completely excising the diseased tissue. Head and neck tumors are also a heterogeneous group of tumors, with many histologic subtypes, each with a unique biologic behavior.
Most of the literature governing the treatment of STSs of the head and neck is based on a few single-institution, retrospective case series and multi-institutional trials. Because of the rarity of these tumors, most statistical analyses have treated them as one group rather than evaluating them separately according to location. Th ese factors challenge clinicians when caring for patients with STS of the head and neck region and its individual subsites.
Materials and methods
Th e National Cancer Institute's Surveillance Epidemiology and End Result (SEER) Program collects and publishes cancer incidence and survival data from populationbased registries that represent approximately 26% of the U.S. population. Th e SEER program began collecting data in 1973 from the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii, and from the metropolitan areas of Detroit and San Francisco-Oakland, in the SEER 9 Registry. SEER has expanded the registries over time to also include Seattle-Puget Sound, Atlanta, Los
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Malignant fi brous histiocytoma. A total of 176 patients with MFH were identifi ed in the SEER 17 Registry. Th ere were 174 (98.9%) males and 2 (1.1%) females, a ratio of 87:1. Of these patients, 168 were white, 1 was black, and the race of 7 patients was unknown. Age of the patients ranged from 17 to 96 years, with a mean of 74 years.
Survival data were available for only 132 of the 176 patients with MFH of the external ear. Th e 5-year survival rates were calculated with respect to the type of surgical intervention (table 3) . Th e observed overall 5-year survival rate for these patients was 69.4%, and the relative 5-year survival rate was 92.0%.
Six patients received external beam radiation therapy; it was unknown whether 1 patient received radiation, and 169 patients did not receive radiation.
Dermatofi brosarcoma. A total of 56 patients with a DFS of the external ear were identifi ed in the SEER 17 Registry. Th ere were 38 (67.9%) males and 18 (32.1%) females, a ratio of approximately 2:1. Within this group, 51 (91.1%) of the patients were white, 2 (3.6%) were black, Angeles, San Jose-Monterey, rural Georgia, the Alaska Native Tumor Registry, Greater California, Kentucky, Louisiana, and New Jersey. Th e most recent registry, SEER 17, was released in 2007 and encompasses all data from 1973 to 2004. Th is database also includes stage at diagnosis, histologic type, and initial therapy.
We Statistical analysis of all data and reference populations was performed using the SEER*Stat version 6.5.2 (National Cancer Institute; Bethesda, Md.). Five-year survival rates were generated for each morphologic cohort and STS of the external ear as a whole using Kaplan-Meier methods. Survival statistics were not included if a cohort consisted of only one patient.
Results

STS-all histologic classifi cations.
A total of 297 patients with external ear sarcoma were identifi ed within the SEER 17 Registry. Th ese represent 0.3% of all STSs diagnosed in the SEER 17 database. Of these patients, 279 were white, 3 black, 1 other (defi ned as American Indian, Alaska Native, Asian/Pacifi c Islander), and and the race of 2 (3.6%) patients was unknown. No patients were identifi ed in the "other" category (American Indian, Alaska Native, Asian/Pacifi c Islander). Ages of the patients ranged from 18 to 89 years, with a mean of 49 years.
Survival data were available for 52 of the 56 patients with DFS. Th e 5-year survival rates were calculated based on the type of surgical intervention (table 4) . Th e observed overall 5-year survival rate for these patients was 93.8%, and the relative 5-year survival rate was 99.8%.
None of the patients diagnosed with DFS of the external ear received radiation.
Discussion
In this study, we calculated the incidence of STS of the external ear among patients in the SEER 17 Registry between 1973 and 2004. Epidemiologic factors of age, race, and gender were evaluated for STS of the external ear. Th e 5-year survival rates for patients with this tumor were calculated using the Kaplan-Meier method and were compared with survival data of published case series reports for head and neck sarcomas.
Histologic classifi cations of the STSs of the external ear were divided based on the most recent WHO classifi cations. Th ese data provided valuable information regarding the clinical behavior of sarcomas of a subsite 
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Among the major series on STS of the head and neck and the oncologic literature, there is a general consensus that the male-to-female ratio for external ear STS is between 1.5:1 and 2:1. 2, 6, 7 In contrast, our data demonstrated a male-to-female ratio of 9.6:1. Our data also demonstrated a mean age at diagnosis that is older than has been reported for head and neck STS. We found the mean age of patients with external ear sarcoma to be 68 years. However, Kraus et al found the median age to be 49 (range 18 to 82), 8 and Farhood et al reported a mean age of 48 years (range 20 to 86). 9 Th e Head and Neck Sarcoma Registry reported an overall 5-year survival of 70% for 214 patients with external ear sarcoma. 7 Other retrospective case series have reported lower survival rates. Le Vay et al reported a 5-year survival of 49%, 6 and Farhood et al reported a 5-year survival of 55%. 9 Th e results of the latter two studies diff er from the 78.5% 5-year survival of patients with STS of the external ear reported in the SEER 17 Easy Choice.
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The Choice is Yours. ™ Registry. In addition, when compared with the reference population, the relative 5-year survival of patients with STS of the external ear was 96.4%. It is diffi cult to analyze the reasons for this discrepancy as there was very little information in the SEER 17 Registry about important prognostic factors, including tumor size, local extent, grade, and margin status. 3, 6, 8 Th e most common histologic classifi cations of STS found in the head and neck vary among experts in the fi eld and depend on location. Th e most common subtype found in the external ear was MFH, followed by DFS and leiomyosarcoma. Regardless of the primary site, leiomyosarcoma is the most common soft -tissue sarcoma, MFH is the second most common, and liposarcoma is the third. 10 Kraus et al found MFH, fi brosarcoma, and leiomyosarcoma to have the highest incidences in the head and neck. 8 Shellenberger et al also found MFH, DFS, and leiomyosarcoma to be the three most common subtypes in the head and neck. 2 We found diff erences in patients' mean age and sex preponderance between the cases of MFH and DFS of the external ear included in the SEER 17 Registry. Th e mean age at diagnosis was 74 years for MFH and 49 years for DFS. Th is age disparity may be a confounding factor in the 5-year survival rates found for each of the subtypes. Th e male-to-female ratio was 87:1 for MFH and 2:1 for DFS.
Our data also demonstrated a diff erence in the overall survival of patients based on histologic classifi cation. We found the overall 5-year survival of patients with MFH of the external ear to be 69.4%, whereas the overall 5-year survival of patients with DFS was 93.8%. However the relative 5-year survival rates of MFH and DFS were, 92.0% and 99.8%, respectively. Comparison of survival rates based on this variable has been limited by lack of uniformity in histologic diagnosis among pathologists and the rarity of the many diff erent subtypes. 7, 11 MFH was introduced as a classifi cation in the 1960s and has since been reevaluated. Many tumors diagnosed as MFH can be reclassifi ed as other well-defi ned entities rather than as a distinct category, which will cause MFH to become an obsolete classifi cation in the future. 12 Our study results suggest a possibly signifi cant diff erence in survival, age, and sex based on this division of histologic subtype when comparing it to STS of the external ear overall, and to the second most common histologic subtype. As more data are compiled, there may be important implications for the therapy and prognosis of STS tumors based on the behavior of individual histologic classifi cations.
Th e National Cancer Institute's SEER database is a powerful resource that can help clinicians characterize rare cancers by gathering data from across the country. However, the database is lacking in data regarding some of the most important factors in defi ning the behavior of these tumors-the grade and the stage. Currently there are three staging systems for soft -tissue sarcomas: the AJCC/UICC TNM system, the Memorial Sloan-Kettering Cancer Center system, and the Ennecking system, which all agree that grade and metastasis are important factors in the stage.
SEER reports data using formats from the SEER Sum-mary Staging Manual 2000, 13 the SEER classifi cation for extent of disease, 14 and the AJCC Cancer Staging Manual, 6th Edition. 15 Th e Collaborative Staging system 16 uses a carefully selected set of data items common to the four staging systems mentioned above (AJCC/UICC, Memorial Sloan-Kettering, Ennecking, and SEER Summary Staging Manual) to describe how far a cancer has spread at the time of diagnosis. Th e multiple systems used to classify the stages of STSs can be confusing. However, they all agree on the major prognostic factors. To further our knowledge of the characteristics of STS of the head and neck, it is crucial that clinicians have a basic understanding of the staging systems and report the individual parameters fully, regardless of which staging system is used to classify the tumor. We also believe that there is room for improvement in the SEER database's handling of external ear sarcoma.
Conclusion
Based on the results of our review of the cases of STS of the external ear reported in the SEER 17 Registry, we found that the location of STS within the head and neck region and the tumor's histologic classifi cation may be important factors in prognosis. Th e SEER 17 database was limited by its lack of reporting of stage, grade, extent, lymph node status, and distant metastases. Sarcomas of the head and neck are unduly believed to have a generally poor prognosis. However, we found that the relative 5-year survival of patients with these tumors originating in the external ear was between 92.0 and 99.8%. STSs of the head and neck are a rare, heterogeneous group of tumors that exhibit unique histologies and malignant behaviors. A consensus staging system and improved reporting in the SEER database should allow for further study of these factors and the development of better treatment protocols.
